drugset / Trial / NCT07565441
Drug-Drug Interactions of JMKX003142 in Healthy Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants. The study consists of five cohorts (Cohorts 1, 2, 3, 4, and 5). A total of 24 participants are planned enrollment in each of Cohorts 1, 2, 3, and 5, while 16 participants are planned for Cohort 4.
Timeline
- Start
- 2026-05-11
- Primary completion
- 2026-11-15
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 100 mg | — |
| Subject | Digoxin | Other / unclassified | 0.25 mg | — |
| Subject | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | Fluconazole | Small molecule | 200 mg | — |
| Subject | JMKX003142 | Unknown | 3 mg | — |
| Subject | JMKX003142 | Unknown | 6 mg | — |
| Subject | Midazolam | Small molecule | 2 mg | — |
| Subject | Omeprazole | Other / unclassified | 40 mg | — |
| Subject | Rosuvastatin | Small molecule | 5 mg | — |